FDA approves Epix's imaging agent for blood vessels
The FDA cleared Epix Pharmaceuticals' Vasovist, a contrast agent for scanning blood vessels. Epix plans to terminate its marketing deal with Bayer AG for the drug in March and seek another partner. Vasovist has been approved in 34 other countries.
Bloomberg
| 12/22
This story published in BIO SmartBrief on 12/23/2008
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|